D-Peptide-Based Prodrug (RD2-Folic Acid) for the Therapy of Alzheimer's Disease

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes a prodrug that combines a specific D-peptide (RD2 or close variants) with folic acid, connected by a linker molecule. The resulting compound is designed to be used as a pharmaceutical treatment for Alzheimer's disease, potentially improving delivery and effectiveness of the therapeutic peptide.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of Alzheimer's disease in human patients
• Enhancement of peptide-based drug delivery for neurological disorders
• Development of other folic acid-linked prodrugs for targeted brain therapies

BenefitsContent extracted from patent full text and abstract with AI.

• May improve the effectiveness of peptide therapies for Alzheimer's disease
• Folic acid can help target delivery to the brain, potentially increasing treatment efficiency
• Could offer fewer side effects compared to conventional Alzheimer's medications
• Provides a template for designing similar prodrugs for other neurological diseases

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

Compound of the general formula A-L-B, wherein A is a polymer comprising at least one monomer, wherein the at least one monomer comprises a peptide with an amino acid sequence selected from the group consisting of SEQ ID NO: 1 (RD2) or homologs with an identity of at least 80% thereof, L is a linker group and B is a substance selected from the group consisting of folic acid, as well as a composition comprising this compound and the use of this compound or composition as a medicament, in particular in the treatment of Alzheimer's disease.